Seer

OverviewSuggest Edit

Seer is a company that develops nanoparticle technology solutions for researchers in the areas of proteomics information. It offers Proteograph an integrated solution comprising consumables, automation instrumentation, and software that performs proteomics analysis.

TypePublic
Founded2017
HQRedwood City, CA, US
Websiteseer.bio

Latest Updates

Employees (est.) (Sept 2020)60
Job Openings12
Revenue (FY, 2021)$6.6 M(+5605%)
Share Price (Jul 2022)$9
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Seer

Omid Farokhzad

Omid Farokhzad

Chair & Chief Executive Officer
Philip Ma

Philip Ma

Founder & Strategic Advisor
David R. Horn

David R. Horn

Chief Financial Officer
Martin Goldberg

Martin Goldberg

VP, Product Development
Omead Ostadan

Omead Ostadan

President & Chief Operating Officer
Asim Siddiqui

Asim Siddiqui

VP, Software and Applications
Show more

Seer Office Locations

Seer has an office in Redwood City
Redwood City, CA, US (HQ)
3800 Bridge Pkwy #102
Show all (1)

Seer Financials and Metrics

Seer Revenue

Seer's revenue was reported to be $6.62 m in FY, 2021
USD

Revenue (Q1, 2022)

3.3m

Gross profit (Q1, 2022)

1.2m

Net income (Q1, 2022)

(23.6m)

EBIT (Q1, 2022)

(23.8m)

Market capitalization (26-Jul-2022)

553.5m

Closing stock price (26-Jul-2022)

9.0

Cash (31-Mar-2022)

225.3m
Seer's current market capitalization is $553.5 m.
Annual
USDFY, 2018FY, 2019FY, 2021

Revenue

116.0k6.6m

Cost of goods sold

3.2m

Gross profit

3.4m

General and administrative expense

3.0m4.6m45.8m
Quarterly
USDQ1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

62.0k837.0k858.0k3.3m

Cost of goods sold

504.0k574.0k2.1m

Gross profit

1.2m

General and administrative expense

10.3m14.3m
Annual
USDFY, 2018FY, 2019FY, 2021

Cash

31.0m17.5m

Accounts Receivable

69.0k326.0k

Current Assets

31.2m86.8m

PP&E

2.4m5.7m
Quarterly
USDQ3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

17.7m445.8m370.7m331.4m225.3m

Accounts Receivable

1.4m412.0k896.0k1.2m2.8m

Prepaid Expenses

3.0m3.2m2.6m4.2m

Inventories

1.5m2.7m2.6m3.6m
Annual
USDFY, 2018FY, 2019FY, 2021

Net Income

(6.3m)(16.0m)(71.2m)

Depreciation and Amortization

31.0k701.0k2.6m

Inventories

(3.6m)

Accounts Payable

323.0k218.0k1.6m
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(10.9m)(19.8m)(16.4m)(33.0m)(51.4m)(23.6m)

Depreciation and Amortization

493.0k1.1m482.0k1.0m1.7m875.0k

Inventories

(990.0k)(2.1m)(2.0m)300.0k

Accounts Payable

(297.0k)(60.0k)(234.0k)(644.0k)302.0k(479.0k)
USDFY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Seer Operating Metrics

Q3, 2020

Patents Issued

5

Patent Applications

25

Seer Acquisitions / Subsidiaries

Company NameDateDeal Size
PrognomIQ, inc

Seer Revenue Breakdown

Embed Graph

Seer revenue breakdown by business segment: 50.0% from Grant and 50.0% from Research

Seer Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Seer Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Seer Online and Social Media Presence

Embed Graph

Seer News and Updates

Seer to Report Second Quarter 2022 Financial Results on August 9, 2022

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter of 2022 on Tuesday, August 9, 2022. Company management will be…

ROSEN, A TOP RANKED LAW FIRM, Encourages Seer, Inc. Investors with Losses to Inquire About Class Action Investigation – SEER

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Seer, Inc. (NASDAQ: SEER) resulting from allegations that Seer may have issued materially misleading business …

Bragar Eagel & Squire, P.C. Is Investigating LifeStance Health, CareDx, Seer, and Laboratory Corp. and Encourages Investors to Contact the Firm

NEW YORK, Jan. 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against LifeStance Health Group, Inc. (NASDAQ: LFST), CareDx, Inc. (NASDAQ: CDNA), Seer, Inc. (NASDAQ: SEER), and Laboratory Corporati…

Updated: Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program

Company has already booked multiple orders and established COEs in three major geographies Company has already booked multiple orders and established COEs in three major geographies

Seer, Discovery Life Sciences and SCIEX Announce First-Of-Its-Kind Proteogenomics Consortium for Large-Scale Studies

Delivery of 100,000 samples of capacity annually to the market, empowering genomics researchers to add deep, unbiased proteomics analysis to their studies Delivery of 100,000 samples of capacity annually to the market, empowering genomics researchers to add deep, unbiased proteomics analysis to thei…

Seer Announces Broad Commercial Release of the Proteograph™ Product Suite and Launches Centers of Excellence Program

Company has already booked multiple orders and established COEs in three major geographies Company has already booked multiple orders and established COEs in three major geographies
Show more

Seer Blogs

Ultra-high coverage of the serum proteome using a multi-nanoparticle based workflow

This poster demonstrates ultra-high coverage of serum proteins with over 5,000 protein groups identified in a 105-sample cohort and over 3,000 protein groups identified on average per sample. Proteins were quantified at 3-5 fold higher levels compared to depleted and un-depleted serum, with 30% enha…

An unbiased multi-omics approach for the detection of pancreatic cancer biomarkers utilizing ion-mobility mass spec and nanoparticle-based Proteograph technology

This poster describes a multi-omics platform facilitating the evaluation of the global proteome and lipidome in a pancreatic cancer cohort and identified multiple putative biomarker candidates across analyte classes for early disease detection.

Deep Profiling of the Spaceflight Plasma Proteome reveals Changes in Reactive Oxygen Species, Telomeric DNA Binding, and Ribosomal Assembly and Biogenesis

This poster demonstractes how comprehensive plasma proteomics profiling of the first all-civilian astronaut crew using the Proteograph Product Suite coupled with LC-MS analysis that offers unique insights to the impact of spaceflight on human health demonstrating even short-term spaceflights can hav…

Combining Proteograph technology with Zeno SWATH DIA acquisition enables the potential for deep, unbiased discovery of biomarkers in blood

This poster demonstrates how the Proteograph Product Suite and Zeno SWATH DIA acquisition workflow that facilitates identification and quantification of thousands of proteins from human plasma without compromising throughput or reproducibility, creating a unique opportunity to detect robust protein …

How do you determine reproducibility of quantification? What is the expected range of reproducibility?

Coefficient of Variation (CV) is a statistic used to compare the extent of variation from one set of data to another, even if the means are very different. CV is a measure of the relative distribution of data points around the average. (Ratio of standard deviation divided by the mean.) […]

What are some of the popular proteomics analysis software?

Many data analysis tools and approaches exist today to analyze proteomics data. Ease-of-use, robustness, scalability, and automation are important factors to consider when selecting your software of choice. For example, MaxQuant, PeptideProphet, Percolator, DIA-NN, MSFragger, MaxQuant, EnclyclopeDIA…
Show more

Seer Frequently Asked Questions

  • When was Seer founded?

    Seer was founded in 2017.

  • Who are Seer key executives?

    Seer's key executives are Omid Farokhzad, Philip Ma and David R. Horn.

  • How many employees does Seer have?

    Seer has 60 employees.

  • What is Seer revenue?

    Latest Seer annual revenue is $6.6 m.

  • What is Seer revenue per employee?

    Latest Seer revenue per employee is $110.3 k.

  • Who are Seer competitors?

    Competitors of Seer include SomaNautix, ExonanoRNA and Onconano Medicine.

  • Where is Seer headquarters?

    Seer headquarters is located at 3800 Bridge Pkwy #102, Redwood City.

  • Where are Seer offices?

    Seer has an office in Redwood City.

  • How many offices does Seer have?

    Seer has 1 office.